-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab Beta in Neuroblastoma Drug Details: Dinutuximab beta (APN-311, Isqette, Qarziba) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APN-01 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APN-01 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APN-01 in Pulmonary Arterial Hypertension Drug Details: APN-01 is under development...
-
Product Insights
Pulmonary Arterial Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Pulmonary Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HTL-0039732 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Cervical Cancer Drug Details: HTL-0039732 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dinutuximab Beta in Leiomyosarcoma Drug Details:Dinutuximab beta (APN-311, Isqette, Qarziba) is a chimeric...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – K-161 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - K-161 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APN-01 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APN-01 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.APN-01 in Pulmonary Arterial Hypertension Drug Details:APN-01 is under development for the...